Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ISSAM I RAAD and DIMITRIOS P KONTOYIANNIS.
ISSAM I RAAD
Connection Strength
6.006
DIMITRIOS P KONTOYIANNIS
  1. Role of ethylene diamine tetra-acetic acid (EDTA) in catheter lock solutions: EDTA enhances the antifungal activity of amphotericin B lipid complex against Candida embedded in biofilm. Int J Antimicrob Agents. 2008 Dec; 32(6):515-8.
    View in: PubMed
    Score: 0.329
  2. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006 May 15; 42(10):1398-403.
    View in: PubMed
    Score: 0.278
  3. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer. 2005 Jun 01; 103(11):2334-7.
    View in: PubMed
    Score: 0.262
  4. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005 Apr 15; 191(8):1350-60.
    View in: PubMed
    Score: 0.258
  5. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand J Infect Dis. 2004; 36(8):564-9.
    View in: PubMed
    Score: 0.237
  6. Sequential exposure of Aspergillus fumigatus to itraconazole and caspofungin: evidence of enhanced in vitro activity. Diagn Microbiol Infect Dis. 2003 Oct; 47(2):415-9.
    View in: PubMed
    Score: 0.233
  7. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003 Jul 15; 98(2):292-9.
    View in: PubMed
    Score: 0.230
  8. Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity. Infect Control Hosp Epidemiol. 2002 Sep; 23(9):542-5.
    View in: PubMed
    Score: 0.216
  9. International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship. medRxiv. 2022 Aug 26.
    View in: PubMed
    Score: 0.216
  10. Impact of Checkpoint Inhibitor Immunotherapy, Primarily Pembrolizumab, on Infection Risk in Patients With Advanced Lung Cancer: A Comparative Retrospective Cohort Study. Clin Infect Dis. 2021 11 02; 73(9):e2697-e2704.
    View in: PubMed
    Score: 0.204
  11. Breakthrough Mucormycosis Developing on Mucorales-Active Antifungals Portrays a Poor Prognosis in Patients with Hematologic Cancer. J Fungi (Basel). 2021 Mar 17; 7(3).
    View in: PubMed
    Score: 0.196
  12. Nitroglycerin-Citrate-Ethanol Catheter Lock Solution Is Highly Effective for In Vitro Eradication of Candida auris Biofilm. Antimicrob Agents Chemother. 2019 07; 63(7).
    View in: PubMed
    Score: 0.173
  13. Culture-Documented Invasive Mold Infections at MD Anderson Cancer Center in Houston, Texas, Pre- and Post-Hurricane Harvey. Open Forum Infect Dis. 2019 Apr; 6(4):ofz138.
    View in: PubMed
    Score: 0.171
  14. Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. J Natl Compr Canc Netw. 2015 Jan; 13(1):41-50.
    View in: PubMed
    Score: 0.127
  15. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. Int J Antimicrob Agents. 2015 Mar; 45(3):283-8.
    View in: PubMed
    Score: 0.125
  16. Drosophila melanogaster as a model to explore the effects of methicillin-resistant Staphylococcus aureus strain type on virulence and response to linezolid treatment. Microb Pathog. 2013 Feb; 55:16-20.
    View in: PubMed
    Score: 0.110
  17. Hepatitis C virus genotype distribution varies by underlying disease status among patients in the same geographic region: a retrospective multicenter study. J Clin Virol. 2012 Jul; 54(3):218-22.
    View in: PubMed
    Score: 0.105
  18. Central venous catheter-associated Nocardia bacteremia in cancer patients. Emerg Infect Dis. 2011 Sep; 17(9):1651-8.
    View in: PubMed
    Score: 0.101
  19. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles. Oncologist. 2011; 16(7):1049-60.
    View in: PubMed
    Score: 0.099
  20. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009 Oct 15; 115(20):4745-52.
    View in: PubMed
    Score: 0.089
  21. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis. 2009 Apr 15; 48(8):1033-41.
    View in: PubMed
    Score: 0.086
  22. Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study. Int J Antimicrob Agents. 2009 Jul; 34(1):95-8.
    View in: PubMed
    Score: 0.085
  23. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis. 2008 Jul 15; 198(2):186-92.
    View in: PubMed
    Score: 0.081
  24. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008 Jun; 112(11):2493-9.
    View in: PubMed
    Score: 0.081
  25. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer. 2008 Mar 15; 112(6):1282-7.
    View in: PubMed
    Score: 0.079
  26. Human herpesvirus-6 DNAemia in immunosuppressed adult patients with leukemia at risk for mold infection. Haematologica. 2008 Jan; 93(1):157-8.
    View in: PubMed
    Score: 0.078
  27. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer. 2007 Sep 15; 110(6):1303-6.
    View in: PubMed
    Score: 0.077
  28. Random plasma concentrations of voriconazole decline over time. J Infect. 2007 Nov; 55(5):e129-30.
    View in: PubMed
    Score: 0.077
  29. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. Clin Ther. 2007 Sep; 29(9):1980-6.
    View in: PubMed
    Score: 0.076
  30. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clin Infect Dis. 2006 Dec 15; 43(12):1580-4.
    View in: PubMed
    Score: 0.072
  31. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica. 2006 Jul; 91(7):986-9.
    View in: PubMed
    Score: 0.070
  32. Pentamidine is active in a neutropenic murine model of acute invasive pulmonary fusariosis. Antimicrob Agents Chemother. 2006 Jan; 50(1):294-7.
    View in: PubMed
    Score: 0.068
  33. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis. 2005 Dec; 5(12):775-85.
    View in: PubMed
    Score: 0.068
  34. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis. 2005 May; 52(1):15-20.
    View in: PubMed
    Score: 0.065
  35. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones. Diagn Microbiol Infect Dis. 2005 Mar; 51(3):215-8.
    View in: PubMed
    Score: 0.064
  36. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer. 2004 Dec 15; 101(12):2859-65.
    View in: PubMed
    Score: 0.063
  37. Invasive aspergillosis in patients with solid tumors. Cancer. 2004 Nov 15; 101(10):2300-2.
    View in: PubMed
    Score: 0.063
  38. Multiple-species candidemia in patients with cancer. Cancer. 2004 Oct 15; 101(8):1860-5.
    View in: PubMed
    Score: 0.063
  39. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer. 2004 Oct 01; 101(7):1594-600.
    View in: PubMed
    Score: 0.063
  40. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis. 2004 Apr 15; 38(8):1119-27.
    View in: PubMed
    Score: 0.060
  41. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer. 2003 Sep 01; 98(5):1039-47.
    View in: PubMed
    Score: 0.058
  42. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore). 2003 Sep; 82(5):309-21.
    View in: PubMed
    Score: 0.058
  43. Infections in patients with aplastic anemia: experience at a tertiary care cancer center. Cancer. 2003 Jul 01; 98(1):86-93.
    View in: PubMed
    Score: 0.057
  44. Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis. 2003 May; 46(1):25-8.
    View in: PubMed
    Score: 0.057
  45. International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship. Elife. 2023 01 30; 12.
    View in: PubMed
    Score: 0.056
  46. Skin lesions associated with Fusarium infection. J Am Acad Dermatol. 2002 Nov; 47(5):659-66.
    View in: PubMed
    Score: 0.055
  47. Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer. Infect Control Hosp Epidemiol. 2002 Sep; 23(9):532-7.
    View in: PubMed
    Score: 0.054
  48. Nocardiosis in cancer patients. Medicine (Baltimore). 2002 Sep; 81(5):388-97.
    View in: PubMed
    Score: 0.054
  49. Lack of catheter infection by the efg1/efg1 cph1/cph1 double-null mutant, a Candida albicans strain that is defective in filamentous growth. Antimicrob Agents Chemother. 2002 Apr; 46(4):1153-5.
    View in: PubMed
    Score: 0.053
  50. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med. 2002 Apr 01; 112(5):380-5.
    View in: PubMed
    Score: 0.053
  51. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016 Feb 20; 387(10020):760-9.
    View in: PubMed
    Score: 0.034
  52. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore). 2010 Jul; 89(4):236-244.
    View in: PubMed
    Score: 0.023
  53. Escherichia coli Pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin Infect Dis. 2010 Feb 01; 50(3):374-80.
    View in: PubMed
    Score: 0.023
  54. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer. 2006 Jun 15; 106(12):2664-71.
    View in: PubMed
    Score: 0.018
  55. Culture-positive and culture-negative endocarditis in patients with cancer: a retrospective observational study, 1994-2004. Medicine (Baltimore). 2006 Mar; 85(2):86-94.
    View in: PubMed
    Score: 0.017
  56. Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality. Clin Lymphoma Myeloma. 2006 Mar; 6(5):393-8.
    View in: PubMed
    Score: 0.017
  57. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients. Int J Infect Dis. 2006 May; 10(3):223-30.
    View in: PubMed
    Score: 0.017
  58. Gastrointestinal cytomegalovirus disease in patients with cancer: a two decade experience in a tertiary care cancer center. Eur J Cancer. 2005 Oct; 41(15):2268-79.
    View in: PubMed
    Score: 0.017
  59. The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer. 2005 Feb 15; 103(4):731-9.
    View in: PubMed
    Score: 0.016
  60. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004 Feb 01; 100(3):568-73.
    View in: PubMed
    Score: 0.015
  61. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004 Feb 01; 100(3):581-9.
    View in: PubMed
    Score: 0.015
  62. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res. 2003 Mar; 9(3):976-80.
    View in: PubMed
    Score: 0.014
  63. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer. 2003 Jan 15; 97(2):450-6.
    View in: PubMed
    Score: 0.014
  64. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection. Antimicrob Agents Chemother. 2002 Nov; 46(11):3499-505.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.